These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 23872910)

  • 1. Evidence of extended (>7 years) activity of bevacizumab and metronomic cyclophosphamide in a patient with platinum-resistant low-grade serous ovarian carcinoma.
    Rose PG; Roma A
    Anticancer Drugs; 2013 Oct; 24(9):986-8. PubMed ID: 23872910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer.
    Sánchez-Muñoz A; Mendiola C; Pérez-Ruiz E; Rodríguez-Sánchez CA; Jurado JM; Alonso-Carrión L; Ghanem I; de Velasco G; Quero-Blanco C; Alba E
    Oncology; 2010; 79(1-2):98-104. PubMed ID: 21079407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.
    Gershenson DM; Sun CC; Bodurka D; Coleman RL; Lu KH; Sood AK; Deavers M; Malpica AL; Kavanagh JJ
    Gynecol Oncol; 2009 Jul; 114(1):48-52. PubMed ID: 19361839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia.
    Garcia AA; Hirte H; Fleming G; Yang D; Tsao-Wei DD; Roman L; Groshen S; Swenson S; Markland F; Gandara D; Scudder S; Morgan R; Chen H; Lenz HJ; Oza AM
    J Clin Oncol; 2008 Jan; 26(1):76-82. PubMed ID: 18165643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity.
    Montagna E; Cancello G; Bagnardi V; Pastrello D; Dellapasqua S; Perri G; Viale G; Veronesi P; Luini A; Intra M; Calleri A; Rampinelli C; Goldhirsch A; Bertolini F; Colleoni M
    Clin Breast Cancer; 2012 Jun; 12(3):207-14. PubMed ID: 22520733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening.
    Simpkins F; Belinson JL; Rose PG
    Gynecol Oncol; 2007 Oct; 107(1):118-23. PubMed ID: 17658587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of bevacizumab in recurrent, platinum-sensitive ovarian cancer.
    Gubbi A; Kendrick JE; Finkler NJ
    Expert Rev Anticancer Ther; 2014 Oct; 14(10):1105-13. PubMed ID: 25189201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclophosphamide "metronomic" chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer.
    Samaritani R; Corrado G; Vizza E; Sbiroli C
    BMC Cancer; 2007 Apr; 7():65. PubMed ID: 17433113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.
    Cannistra SA; Matulonis UA; Penson RT; Hambleton J; Dupont J; Mackey H; Douglas J; Burger RA; Armstrong D; Wenham R; McGuire W
    J Clin Oncol; 2007 Nov; 25(33):5180-6. PubMed ID: 18024865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small reduction in quality of life seen with bevacizumab maintenance in patients with ovarian cancer.
    Barton MK
    CA Cancer J Clin; 2013; 63(4):219-20. PubMed ID: 23733586
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-term remission in a patient with heavily pretreated, advanced ovarian cancer achieved by bevacizumab and metronomic cyclophosphamide treatment.
    Aigner J; Bischofs E; Hallscheidt P; Sohn C; Schneeweiss A; Eichbaum M
    Anticancer Drugs; 2011 Nov; 22(10):1030-3. PubMed ID: 21970854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Success of bevacizumab trials raises questions for future studies.
    Tuma RS
    J Natl Cancer Inst; 2005 Jul; 97(13):950-1. PubMed ID: 15998941
    [No Abstract]   [Full Text] [Related]  

  • 13. Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer.
    Jurado JM; Sánchez A; Pajares B; Pérez E; Alonso L; Alba E
    Clin Transl Oncol; 2008 Sep; 10(9):583-6. PubMed ID: 18796376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role for cytotoxic chemotherapy in patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series.
    Chamberlain MC
    Expert Rev Neurother; 2012 Aug; 12(8):929-36. PubMed ID: 23002937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unusual ischemic complication of bevacizumab treatment for metastatic colorectal carcinoma.
    Ryan EM; Hanly A; Morrin MM; McNamara DA
    J Clin Oncol; 2013 Oct; 31(30):e433-4. PubMed ID: 23775957
    [No Abstract]   [Full Text] [Related]  

  • 16. A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC).
    Raez LE; Santos ES; Webb RT; Wade J; Brito RA; Karr M; Kennah A; Childs BH
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1103-10. PubMed ID: 24057043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential bevacizumab and oral cyclophosphamide for recurrent ovarian cancer.
    Matulonis UA; Pereira L; Liu J; Lee H; Lee J; Whalen C; Campos S; Atkinson T; Hill M; Berlin S
    Gynecol Oncol; 2012 Jul; 126(1):41-6. PubMed ID: 22487536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experience with bevacizumab in the management of epithelial ovarian cancer.
    Burger RA
    J Clin Oncol; 2007 Jul; 25(20):2902-8. PubMed ID: 17617521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Durable response in platinum refractory small cell carcinoma of the ovary hypercalcemic type treated with combination pembrolizumab, oral cyclophosphamide, and bevacizumab.
    Shu MK; Moses E; Korangy E; McGrath J; Reyes HD
    Int J Gynecol Cancer; 2024 May; 34(5):777-782. PubMed ID: 38719275
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.